title: How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance.
authors.forename: T
authors.initials: T
authors.lastname: Zenz
authors.forename: S
authors.initials: S
authors.lastname: Häbe
authors.forename: T
authors.initials: T
authors.lastname: Denzel
authors.forename: D
authors.initials: D
authors.lastname: Winkler
authors.forename: H
authors.initials: H
authors.lastname: Döhner
authors.forename: S
authors.initials: S
authors.lastname: Stilgenbauer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D017809:Fatal Outcome; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab